Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279417 · ClinicalTrials.gov registry record · Phase 2
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
NCT05279417 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 251 participants.
The verdict
NCT05279417, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
Study Summary
This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
Interventions
- DRUG Placebo oral tablet
- DRUG Methotrexate
- DRUG ATI-450 50 mg oral tablet BID
- DRUG ATI-450 20 mg oral tablet BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279417
The ClinicalTrials.gov registry entry for NCT05279417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo oral tablet is the first listed.
NCT05279417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05279417 about?
NCT05279417 is a clinical study titled "ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)". This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.
What is the current status of trial NCT05279417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2022-02-01. Estimated completion is 2023-10-11.
What interventions are being tested in trial NCT05279417?
The interventions under investigation include: Placebo oral tablet (DRUG), Methotrexate (DRUG), ATI-450 50 mg oral tablet BID (DRUG), ATI-450 20 mg oral tablet BID (DRUG).
Who is sponsoring clinical trial NCT05279417?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.